

January 29, 2022

Corporate Relationship Department BSE Limited, PJ Towers, Dalal Street, Mumbai- 400001

Dear Sirs

Sub: Unaudited Financial Results and Limited Review Report for the quarter and nine months ended December 31, 2021- Outcome of the Board meeting Ref: 1) Regulation 33 of SEBI (LODR) Regulations 2015

2) Script Code: 526783

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that in terms of Regulation 30, 33 and other applicable provisions of Listing Regulations, the Board of Directors of the Company at its meeting held on January 29, 2022 commenced at 12.30 P.M and concluded at 2.00 P.M have inter alia transacted the following:

1) Approved the Un-audited financial results of the Company for the quarter and nine months ended December 31, 2021. In this regard, please find enclosed the following:

- i. Statement showing the Un-audited Financial Results for the quarter and nine months ended
- ii. Limited Review Report issued by the Statutory Auditors on the above Financial Results of the Company.

2) The Company has made arrangement for release of the Un-audited Financial results for the quarter and nine months ended December 31, 2021 in the newspaper as per the requirement of the SEBI (LODR) Regulation, 2015.

Kindly take the above information on record.

Thanking you,

Yours faithfully For DR. AGARWAL'S EYE HOSPITAL LIMITED

MEENAKSHI JAYARAMAN COMPANY SECRETARY



Dr. Agarwal's Eye Hospital Ltd.

Regd. & Corporate Office :

3rd Floor, Buhari Towers, No.4, Moores Road, off Greams Road, Near Asan Memorial School, Chennai - 600 006. Tel. : +91 44 4378 7777 | +91 44 4378 7778 | CIN : L85110TN1994PLC027366 | GST No. : 33AAACD2373G1Z2 Email : info@dragarwal.com | Website : www.dragarwal.com

Tel: +91 44 6688 5000 Fax: +91 44 6688 5050

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

- 1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**

Chartered Accountants (Firm's Registration No. 008072S)

Ananthi Amarnath (Partner) (Membership No. 209252)

Place: Chennai Date: January 29, 2022 UDIN: 22209252AAAAAN8584



Dr. Agarwal's Eye Hospital Limited CIN: L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006

	Phone No. 91-44-39916669 Website : www.dragarwal.com E-mail : investor@dragarwal.com						
		(Amount Rs	. in Lakhs except earnings p	er share data)			
St	tatement of Unaudited Financial Res	sults for the Quarter and Nine Months End	ded 31 December 2021				
		Quarter Ended	Nine months ended	Year Ended			

S.N. e. Particulars 31 December 31 December (a) December (b) Other income (b) Other income 31 December (b) Other income 31 December (c) Other income	-	Ouarter Ended							
o. Particulars 21 Descrine 31 Descrine 32 Descrine 33 Descrine 31	S.N	S.N		Quarter Ended		Nine months ended		Year Ended	
Unsatisfield Unsatisfield<	0.	Particulars							
Income (a) Revolue from Operations (b) Other income 5,647,265 5,820,25 4,273,64 14,555,05 8,809,48 13,980,00 2 (a) Revolue from Operations (b) Other income 5,647,49 5,862,80 4,275,64 14,555,05 8,809,48 13,980,00 2 (a) Purchase of Stock-in-Trade (b) Changes in inventories of Stock-in-Trade (b) Changes in inventories of Stock-in-Trade (c) Consultancy Charges 643,11 688,05 466,65 1,711,27 891,12 1,508,33 (c) Surgical Lans, including other consumables (c) Consultancy Charges 712,58 700,18 505,14 7,423,01 1,008,66 1,655,88 (c) Consultancy Charges 1,066,93 774,02 1,008,66 1,675,88 667,774 2,080,20 1,135,82 2,235,55 6,237,45 2,231,55 6,31,73 1,232,23 1,393,83 1,373,83 8,91,73 1,465,98 3,662,10 1,24,84,83 1,232,23 1,393,83 1,373,83 1,374,83 1,374,83 1,374,83 1,348,85 (a) Revort Spenses 753,03 772,755 1,232,23 1,393,84 1,398,85 1,315,97 614,10 2,307,67 (
Image: space	1	Income	Gildudited	onaddited	Unaudited	Unaudited	Unaudited	Audited	
Box 10.201/min 2.261 2.265 2.9945 3.82.25 1.2003 Total Income 5.872.49 5.862.80 4.275.20 14.654.50 8.847.73 14.061.57 2 Expense (b) Changes in Inventories of Stock-in-Trade (b) Changes in Inventories of Stock-in-Trade (c) Consultancy Charges (e) Employee Benefit Expenses (e) Employee Benefit Expenses (f) Rent (f) Oner Expenses (f) Rent (f) Oner Expenses Total Expenses Total Expenses Total Expenses For If / Loss) before Exceptional Items and Tax (1-2) (f) Other Expenses For If / Loss) before Exceptional Items and Tax (1-2) (f) Other Expenses For If / Loss) before Exceptional Items and Tax (1-2) (f) Rent (f) Consultancy (f) Other Expenses For If / Loss) before Exceptional Items - Current Tax -			5 647 65	5 820 25	1 272 64	14 555 05	8 800 40	12 000 00	
Total Income 5,672.49 5,862.80 4,276.20 14,565.50 8,897.73 14,001.30 2 Expenses (a) Purchas of Stock-in-Trade 643.11 6688.06 1,711.27 89.112 1,508.33 (b) Charges in Inventories of Stock-in-Trade 643.11 6688.06 627.74 2,005.00 1,513.74 2,050.66 1,675.48 (c) Surgical Lans including other consumables 712.58 700.18 505.14 1,742.30 1,008.66 1,625.48 (d) Consumery Charges 761.03 766.06 2,231.22 3,217.14 2,806.02 2,313.12 1,908.50 3,217.14 2,909.20 1,513.74 2,205.06 3,217.14 2,909.20 1,313.74 2,205.06 3,217.14 2,909.20 1,313.74 2,205.06 3,217.14 2,909.20 1,313.74 2,205.06 3,217.14 2,909.20 1,313.74 2,205.06 3,217.14 2,909.97 1,31.84 3,217.21 3,317.81 3,348.85 (g) Depretation and Amortisation Expense 4,538.33 4,546.83 3,662.10 1,2,346.83 9,573.31			A						
Image: space set stack-in-Trade Junch State set set stack-in-Trade set set set set set set stack-in-Trade set set set set set set set set set se									
iii) iii) Purchase of Stock-In-Trade 643.11 668.06 466.65 1,711.27 891.12 1,508.33 iii) Changes in Inventories of Stock-In-Trade - Decrease / (increase) 6.47 (66.83) (7.97) (60.05) 117.53 116.53 (c) Surgical Lens including other consumables 717.55 700.18 602.77.4 2,0200 1,513.74 2,215.06 (c) Consultancy Charges 761.03 776.08 602.77.4 2,289.05 2,331.55 3,217.14 (c) Enginee Benefit Expenses 1,036.52 973.85 831.72 2,894.05 2,331.55 3,217.14 1,209.95 (i) Other Spenses 445.566 505.16 492.26 1,474.59 1,348.32 1,939.31 1,348.32 3 Profit / (Loss) before Exceptional Items and Tax (1-2) 1,088.96 1,315.97 614.10 2,307.67 (409.58) 573.28 4 Exceptional Items - - - - - - - - - - -			5,072.45	5,002.00	4,270.20	14,034.50	0,047.75	14,001.53	
iii) iii) Purchase of Stock-In-Trade 643.11 668.06 466.65 1,711.27 891.12 1,508.33 iii) Changes in Inventories of Stock-In-Trade - Decrease / (increase) 6.47 (66.83) (7.97) (60.05) 117.53 116.53 (c) Surgical Lens including other consumables 717.55 700.18 602.77.4 2,0200 1,513.74 2,215.06 (c) Consultancy Charges 761.03 776.08 602.77.4 2,289.05 2,331.55 3,217.14 (c) Enginee Benefit Expenses 1,036.52 973.85 831.72 2,894.05 2,331.55 3,217.14 1,209.95 (i) Other Spenses 445.566 505.16 492.26 1,474.59 1,348.32 1,939.31 1,348.32 3 Profit / (Loss) before Exceptional Items and Tax (1-2) 1,088.96 1,315.97 614.10 2,307.67 (409.58) 573.28 4 Exceptional Items - - - - - - - - - - -	2	Expenses							
International of Stock-in-Trade - Decrease / Intervase 6.77 7.72 2.72 7.72 2.72 7.72			643.11	688.06	466.65	1 711 27	801 12	1 509 22	
Increase) 6-67 (6-683) (7.97) (6.069) 147.69 116.33 (1) Corgulation (Less including other consumables 717.58 700.18 602.774 2.020.00 1.51.374 2.225.06 (a) Employee Benefit Expenses 1.006.62 973.85 831.72 2.894.05 2.331.55 3.217.14 (b) Employee Benefit Expenses 1.055.64 1492.26 1.474.59 1.635.8 64.37 (b) Depreciation and Amortisation Expense 465.56 505.16 1492.26 1.474.59 1.317.81 1.008.96 1.825.73 1.232.23 1.909.86 (c) Other Expenses 4.584.83 3.662.10 1.2,346.83 9.257.31 1.348.825 3 Profit / (Loss) before Exceptional Items and Tax (1-2) 1.088.96 1.315.97 614.10 2.307.67 (409.58) 573.28 4 Exceptional Items -		(b) Changes in Inventories of Stock-in-Trade - Decrease /				1,/11.2/	091.12	1,506.55	
i di Consultany Charges 751.03 766.08 62.74 2.092.00 1.513.74 2.205.00 (e) Employee Benefit Expenses 1.036.30 973.85 831.72 2,894.05 2,331.55 3,217.14 (g) Depreciation and Amortisation Expense 1453.36 152.41 183.61 450.13 467.98 63.4.74 (g) Depreciation and Amortisation Expense 465.56 505.16 492.25 1.474.59 1.433.22 1.909.95 (i) Other Expenses 735.03 727.95 495.60 1.223.73 1.232.73 1.232.31 1.31.488.25 3 Profit / (Loss) before Exceptional Items and Tax (1-2) 1.088.96 1.315.97 614.10 2.307.67 (409.58) 573.28 4 Exceptional Items		(Increase)	6.47	(66.83)	(7.97)	(60.69)	147.69	116.33	
i di Consultany Charges 751.03 766.08 62.74 2.092.00 1.513.74 2.205.00 (e) Employee Benefit Expenses 1.036.30 973.85 831.72 2,894.05 2,331.55 3,217.14 (g) Depreciation and Amortisation Expense 1453.36 152.41 183.61 450.13 467.98 63.4.74 (g) Depreciation and Amortisation Expense 465.56 505.16 492.25 1.474.59 1.433.22 1.909.95 (i) Other Expenses 735.03 727.95 495.60 1.223.73 1.232.73 1.232.31 1.31.488.25 3 Profit / (Loss) before Exceptional Items and Tax (1-2) 1.088.96 1.315.97 614.10 2.307.67 (409.58) 573.28 4 Exceptional Items		(c) Surgical Lens including other consumables	717.58	700.18	505.14	1.742.30	1.008.66	1,625,48	
(e) Employee Benefit Expenses 1,036.92 973.85 817.2 2,894.05 2,331.85 3,217.1 (f) Finance Cots 153.36 152.41 153.61 450.13 467.98 634.74 (g) Depreciation and Amortisation Expense 163.36 152.41 153.61 450.13 467.98 634.74 (g) Depreciation and Amortisation Expense 64.37 99.97 87.35 217.45 23.11.2 313.84 (f) Finance Cots 458.35 4546.88 3.662.10 12.346.83 9.257.31 13.488.25 3 Profit / (Loss) before Exceptional Items and Tax (1-2) 1,088.96 1,315.97 614.10 2,307.67 (409.58) 573.28 4 Exceptional Items - - - - - 258.80 565.27 - 258.80 565.73 - 258.80 565.73 - 258.80 565.73 - 258.80 565.73 - 258.80 565.73 - 258.80 565.73 - 258.80 565.73 - 2565.73		(d) Consultancy Charges						,	
(i) Finance Costs (g) Deprediction and Amortisation Expense (h) Rent (i) Other Expenses 153.36 (s) 573.03 152.41 (s) 22, 1474.59 (s) 231.12 (s) 231.23 1,467.98 (s) 231.23 (s) 231.23 1,467.98 (s) 231.23 1,309.95 (s) 1,474.59 (s) 231.12 (s) 235.71 1,437.82 (s) 231.23 1,909.95 (s) 373.23 3 Profit / (Loss) before Exceptional Items and Tax (1-2) 1,088.96 1,315.97 614.10 2,307.67 (409.58) 573.28 4 Exceptional Items -		(e) Employee Benefit Expenses	1,036.92						
Image:		(f) Finance Costs	153.36	152.41					
Initial field of the spenses 64.37 72503 799.97 72503 7235 727275 221.45 495.60 221.12 1.2346.83 21.12 1.153.41 3 Profit / (Loss) before Exceptional Items and Tax (1-2) 1,088.96 1,315.97 614.10 2,307.67 (409.58) 573.28 4 Exceptional Items		(g) Depreciation and Amortisation Expense	465.66	505.16	492.26				
In the second			64.37	99.97	87.35	217.45	a second s		
Total Expenses 4,583.53 4,546.83 3,662.10 12,346.83 9,257.31 13,488.25 3 Profit / (Loss) before Exceptional Items and Tax (1-2) 1,088.96 1,315.97 614.10 2,307.67 (409.58) 573.28 4 Exceptional Items - <		A CONTRACT OF A	735.03	727.95	495.60	1,825.73	1,232.23		
4 Exceptional Items		Total Expenses	4,583.53	4,546.83	3,662.10	12,346.83		13,488.25	
4 Exceptional Items									
5 Profit / (Loss) before Tax (3-4) 1,088.96 1,315.97 614.10 2,307.67 (409.58) 573.28 6 Tax Expense - Current Tax - Deferred Tax 297.99 354.28 652.27 - 258.80 7 Net Profit / (Loss) after tax for the period (5-6) 815.11 980.26 443.19 1,723.05 (319.13) (143.86) 8 Other Comprehensive Income (a) Items that will not be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) on defined benefit obligation - Actuarial gain / (loss) on defined benefit obligation - Tax on items that will not be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax) 0.05 0.02 (8.70) 0.09 (22.05) 0.07 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56) 0.07 (16.55) 0.05 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56) 0.07 (16.55) 0.05 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56) 0.07 (16.55) 0.05 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56)	3	Profit / (Loss) before Exceptional Items and Tax (1-2)	1,088.96	1,315.97	614.10	2,307.67	(409.58)	573.28	
5 Profit / (Loss) before Tax (3-4) 1,088.96 1,315.97 614.10 2,307.67 (409.58) 573.28 6 Tax Expense - Current Tax - Deferred Tax 297.99 354.28 652.27 - 258.80 7 Net Profit / (Loss) after tax for the period (5-6) 815.11 980.26 443.19 1,723.05 (319.13) (143.86) 8 Other Comprehensive Income (a) Items that will not be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) on defined benefit obligation - Actuarial gain / (loss) on defined benefit obligation - Tax on items that will not be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax) 0.05 0.02 (8.70) 0.09 (22.05) 0.07 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56) 0.07 (16.55) 0.05 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56) 0.07 (16.55) 0.05 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56) 0.07 (16.55) 0.05 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56)		-							
6 Tax Expense - Current Tax - Tax related to Prior years - Deferred Tax 297.99 354.28 - 652.27 - 258.80 7 Net Profit / [Loss] after tax for the period (5-6) 815.11 980.26 443.19 1,723.05 (319.13) (143.86) 8 Other Comprehensive Income (a) Items that will not be reclassified to the Statement of Profit and Loss 0.05 0.02 (8.70) 0.09 (22.05) 0.07 10 Paid-up equity share capital (Face value Rs.10/- each) 470.00 <td< th=""><th>4</th><th>Exceptional Items</th><th>-</th><th>-</th><th>-</th><th>-</th><th>-</th><th>-</th></td<>	4	Exceptional Items	-	-	-	-	-	-	
6 Tax Expense - Current Tax - Tax related to Prior years - Deferred Tax 297.99 354.28 - 652.27 - 258.80 7 Net Profit / [Loss] after tax for the period (5-6) 815.11 980.26 443.19 1,723.05 (319.13) (143.86) 8 Other Comprehensive Income (a) Items that will not be reclassified to the Statement of Profit and Loss 0.05 0.02 (8.70) 0.09 (22.05) 0.07 10 Paid-up equity share capital (Face value Rs.10/- each) 470.00 <td< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></td<>									
- Current Tax - 297.99 354.28 - 652.27 - 258.80 - Tax related to Prior years . <	5	Profit / (Loss) before Tax (3-4)	1,088.96	1,315.97	614.10	2,307.67	(409.58)	573.28	
- Current Tax - 297.99 354.28 - 652.27 - 258.80 - Tax related to Prior years . <		T							
- Tax related to Prior years - Deferred Tax - Tax related to Prior years (24.14) - Tax related to Prior years (105.44) - Tax related to Prior years (105.44) - Tax relater years (105.44) 0 ther Comprehensive Income / (loss) on defined benefit obligation rotal Other Comprehensive Income / (Loss) (net of tax) - Tax relater years (10.01) - Tax relater years (10.02) - Tax relater years (10.02) <th>6</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	6								
- Deferred Tax (24.14) (18.57) 170.91 (67.65) (90.45) (105.48) 7 Net Profit/(Loss) after tax for the period (5-6) 815.11 980.26 443.19 1,723.05 (319.13) (143.86) 8 Other Comprehensive Income (a) Items that will not be reclassified to the Statement of Profit and Loss - Actuarial gain / (loss) on defined benefit obligation - Tax on items that will not be reclassified to the Statement of Profit and Loss (b) Items that will be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax) 0.05 0.022 (8.70) 0.09 (22.05) 0.07 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56) 0.07 (16.55) 0.05 9 Total Comprehensive Income / (Loss) (net of tax) 0.04 0.02 (6.56) 0.07 (16.55) 0.05 10 Pald-up equity share capital (Face value Rs.10/- each) 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 470.00 4,996.28			297.99	354.28	-	652.27	-		
Image: Constraint of the second sec			-	-	-	-	-		
8 Other Comprehensive Income (a) Items that will not be reclassified to the Statement of Profit and Loss - Actuarial gain / (loss) on defined benefit obligation - Tax on items that will not be reclassified to the Statement of Profit and Loss (b) Items that will not be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax) 0.05 0.02 (8.70) 0.09 (22.05) 0.07 9 Total Comprehensive Income / (Loss) (r+8) 815.15 980.28 436.63 1,723.12 (335.68) (143.81) 10 Paid-up equity share capital (Face value Rs.10/- each) 470.00 470.0		- Deleneu Tax	(24.14)	(18.57)	170.91	(67.65)	(90.45)	(105.44)	
8 Other Comprehensive Income (a) Items that will not be reclassified to the Statement of Profit and Loss - Actuarial gain / (loss) on defined benefit obligation - Tax on items that will not be reclassified to the Statement of Profit and Loss (b) Items that will not be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax) 0.05 0.02 (8.70) 0.09 (22.05) 0.07 9 Total Comprehensive Income / (Loss) (r+8) 815.15 980.28 436.63 1,723.12 (335.68) (143.81) 10 Paid-up equity share capital (Face value Rs.10/- each) 470.00 470.0	7	Net Profit/ (Loss) after tax for the period (5-6)	815.11	980.26	443.19	1 722 05	/210 12\	(142.96)	
(a) Items that will not be reclassified to the Statement of Profit and Loss - Actuarial gain / (loss) on defined benefit obligation - Tax on items that will not be reclassified to the Statement of Profit and Loss (b) Items that will be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax)0.05 0.050.02 0.07 0.01(8.70) 2.140.09 (0.02)(22.05) 5.500.07 (0.02)9Total Other Comprehensive Income / (Loss) (net of tax)0.040.02(6.56)0.07(16.55)0.059Total Comprehensive Income / (Loss) (7+8)815.15980.28436.631.723.12(335.68)(143.81)10Paid-up equity share capital (Face value Rs.10/- each)470.00470.00470.00470.00470.00470.0011Reserves (Other Equity)III20.869.4336.66(6.79)(3.06) (1.02)(3.06)12Earnings Per Equity Share (EPS) (Face value of Rs.10/- each) (a) Basic (b) Diluted17.3420.869.4336.66(6.79)(3.06) (3.06)		, (, (),	010111	500.20	443.15	1,723.05	(313.13)	(145.80)	
(a) Items that will not be reclassified to the Statement of Profit and Loss - Actuarial gain / (loss) on defined benefit obligation - Tax on items that will not be reclassified to the Statement of Profit and Loss (b) Items that will be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax)0.05 0.050.02 0.07 0.01(8.70) 2.140.09 (0.02)(22.05) 5.500.07 (0.02)9Total Other Comprehensive Income / (Loss) (net of tax)0.040.02(6.56)0.07(16.55)0.059Total Comprehensive Income / (Loss) (7+8)815.15980.28436.631.723.12(335.68)(143.81)10Paid-up equity share capital (Face value Rs.10/- each)470.00470.00470.00470.00470.00470.0011Reserves (Other Equity)III20.869.4336.66(6.79)(3.06) (1.02)(3.06)12Earnings Per Equity Share (EPS) (Face value of Rs.10/- each) (a) Basic (b) Diluted17.3420.869.4336.66(6.79)(3.06) (3.06)	8	Other Comprehensive Income							
Profit and Loss - Actuarial gain / (loss) on defined benefit obligation - Tax on items that will not be reclassified to the Statement of Profit and Loss (b) Items that will be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax)0.05 (0.01)0.02 (8.70)0.09 (8.70)(22.05) (0.02)0.07 (0.02)9Total Comprehensive Income / (Loss) (net of tax)0.040.02(6.56)0.07(16.55)0.059Total Comprehensive Income / (Loss) (7+8)815.15980.28436.631,723.12(335.68)(143.81)10Paid-up equity share capital (Face value Rs.10/- each)470.00470.00470.00470.00470.00470.00470.0011Reserves (Other Equity)II									
- Tax on items that will not be reclassified to the Statement of Profit and Loss (b) Items that will be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax)(0.01)-2.14(0.02)5.50(0.02)9Total Comprehensive Income / (Loss) (net of tax)0.040.02(6.56)0.07(16.55)0.059Total Comprehensive Income / (Loss) (7+8)815.15980.28436.631,723.12(335.68)(143.81)10Paid-up equity share capital (Face value Rs.10/- each)470.00470.00470.00470.00470.00470.0011Reserves (Other Equity)Image of tax in the state of tax in tax in the state of tax in tax									
- Tax on items that will not be reclassified to the Statement of Profit and Loss (b) Items that will be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax)(0.01)-2.14(0.02)5.50(0.02)9Total Comprehensive Income / (Loss) (net of tax)0.040.02(6.56)0.07(16.55)0.059Total Comprehensive Income / (Loss) (7+8)815.15980.28436.631,723.12(335.68)(143.81)10Paid-up equity share capital (Face value Rs.10/- each)470.00470.00470.00470.00470.0011Reserves (Other Equity)4.996.2812Earnings Per Equity Share (EPS) (Face value of Rs.10/- each)17.34 (not20.869.43 (not36.66 (not(6.79) (3.06)(3.06) (3.06)		- Actuarial gain / (loss) on defined benefit obligation	0.05	0.02	(8.70)	0.09	(22.05)	0.07	
Statement of Profit and Loss (b) Items that will be reclassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax)0.040.02(6.04)19Total Comprehensive Income / (Loss) (net of tax)0.040.02(6.56)0.07(16.55)0.059Total Comprehensive Income / (Loss) (7+8)815.15980.28436.631,723.12(335.68)(143.81)10Paid-up equity share capital (Face value Rs.10/- each)470.00470.00470.00470.00470.0011Reserves (Other Equity)		- Tax on items that will not be reclassified to the	(0.01)	-					
and Loss Total Other Comprehensive Income / (Loss) (net of tax)Image: Comprehensive Income / (Loss) (ne						(0.01)	0.00	(0.02)	
Total Other Comprehensive Income / (Loss) (net of tax)0.040.02(6.56)0.07(16.55)0.059Total Comprehensive Income/ (Loss) (7+8)815.15980.28436.631,723.12(335.68)(143.81)10Paid-up equity share capital (Face value Rs.10/- each)470.00470.00470.00470.00470.0011Reserves (Other Equity)Image: Comprehensive Income (EPS) (Face value of Rs.10/- each)17.3420.869.4336.66(6.79)(3.06)12Earnings Per Equity Share (EPS) (Face value of Rs.10/- each)17.3420.869.4336.66(6.79)(3.06)13Image: Comprehensive Income (EPS) (Face value of Rs.10/- each)Image: Comprehensive Income (Image: Comprehensity Income (Image: Comprehes		(b) Items that will be reclassified to the Statement of Profit	-	-	-	-	-		
9 Total Comprehensive Income/ (Loss) (7+8) 815.15 980.28 436.63 1,723.12 (335.68) (143.81) 10 Paid-up equity share capital (Face value Rs.10/- each) 470.00 4.996.28<									
10 Paid-up equity share capital (Face value Rs.10/- each) 470.00 4.996.28 10.00		Total Other Comprehensive Income / (Loss) (net of tax)	0.04	0.02	(6.56)	0.07	(16.55)	0.05	
10 Paid-up equity share capital (Face value Rs.10/- each) 470.00 4.996.28 10.00	0								
11 Reserves (Other Equity)	9	Comprehensive Income/ (Loss) (7+8)	815.15	980.28	436.63	1,723.12	(335.68)	(143.81)	
11 Reserves (Other Equity)	10	Paid-up equity share capital (Face value Rs 10/, each)	470.00	470.00	470.00	470.00	170.00		
12 Earnings Per Equity Share (EPS) (Face value of Rs.10/- each) (a) Basic (b) Diluted 17.34 20.86 9.43 36.66 (6.79) (3.06) (mot (not	10	and up equity share capital (race value NS.TU/- EdCII)	470.00	470.00	470.00	470.00	470.00	470.00	
12 Earnings Per Equity Share (EPS) (Face value of Rs.10/- each) (a) Basic (b) Diluted 17.34 20.86 9.43 36.66 (6.79) (3.06) (mot (not	11	Reserves (Other Equity)						1 006 20	
(a) Basic 17.34 20.86 9.43 36.66 (6.79) (3.06) (b) Diluted 17.34 20.86 9.43 36.66 (6.79) (3.06) (not (not (not (not (not (not (not (not								4,990.28	
(a) Basic 17.34 20.86 9.43 36.66 (6.79) (3.06) (b) Diluted 17.34 20.86 9.43 36.66 (6.79) (3.06) (not (not (not (not (not (not (not (not	12	Earnings Per Equity Share (EPS) (Face value of Rs.10/- each)							
(b) Diluted 17.34 20.86 9.43 36.66 (6.79) (3.06) (not			17.34	20.86	9 43	36.66	16 70)	12 061	
(not (not (not (not (not (Annualised)									
(Annualised)									
						and the second second second	Annualised)	(Annualised)	



¥



Dr. Agarwal's Eye Hospital Limited CIN: L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006 Phone No. 91-44-39916669 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Notes:

- 1 The above unaudited financial results have been reviewed by the Audit Committee, approved and taken on record by the Board of Directors in their meeting held on 29 January 2022. The above results for the quarter and nine months ended 31 December 2021 has also been subject to limited review by the Statutory Auditors of the Company.
- 2 The Company operates in a single segment i.e. "Eye Care related sales and services" and hence, does not have any additional disclosures to be made under Ind AS 108 Operating Segments.
- 3 The Company has considered internal and certain external sources of information including credit reports, economic forecasts and industry reports up to the date of approval of the financial results in determining the impact on various elements of its financial results relating to COVID-19 pandemic. The Company has used the principles of prudence in applying judgments, estimates and assumptions including sensitivity analysis and based on the current estimates. The Company expects to fully recover the carrying amount of trade receivables and right-to-use asset. The eventual outcome of impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results.
- 4 The Code on Wages 2019 and Code on Social Security 2020 "the Codes" relating to employee compensation and post-employment benefits received the Presidential Assent in September 2020 and the Code has been published in the Official Gazette. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period when the Code becomes effective.

Place : Chennai Date: 29 January 2022

IR H Chennai

By order of the Board

Dr. Amar Agarwal **Chairman & Managing Director** DIN No. 00435684



Dr. Agarwal's Eye Hospital Limited CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006 Phone No. 91-44-39916669 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in Rs. Lakhs)						
	1 ^			- 0-	1	11.
		moun	NT 11	n Rc	12	khcl

Statement of Unavelited Figure 1.1 Parts				(Amount	in Rs. Lakns
Statement of Unaudited Financial Results for	the Quarter ar	nd Nine Month	s Ended 31 Dec	ember 2021	
Particulars	Quarter Ended 31 December 2021	Quarter Ended 31 December 2020	Nine Months Ended 31 December 2021	Nine Months Ended 31 December 2020	For the Year Ended 31 March 2021
Revenue from Operations	5,647.65	4,273.64	14,555.05		13,980.90
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	1.088.96			(409.58)	573.28
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	1.088.96	614.10	2,307.67	(409.58)	
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)					575.28
Total Comprehensive Income for the period [Comprising Profit / (Loss)	815.11	443.19	1,723.05	(319.13)	(143.86
for the period (after tax) and Other Comprehensive Income (after tax)]	815.15	436.63	1,723.12	(335.68)	(143.81)
Paid-up Equity Share Capital (Face Value of Rs.10/- each)	470.00	470.00	470.00	470.00	470.00
Reserves (Other Equity)	-	-	-	-	4,996.28
Earnings Per Share (for continuing and discontinued operations) (Face Value of Rs. 10/- each):					.,
(a) Basic	17.34	9.43	36.66	(6.79)	(2.00)
b) Diluted	17.34	9.43	36.66	(6.79)	(3.06)
			(not Annualised)	(not Annualicad)	
		((inst Annualiseu)	(not Annualised)	(Annualised)

Notes:

1) The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Unaudited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com).

Place: Chennai Date: 29 January 2022



By order of the Board

Dr. Amar Agarwal Chairman & Managing Director DIN No. 00435684